Life-saving technology

With the aim of making this life-saving technology available to all Canadians even after the COVID-19 pandemic recedes, Project ACTT is also:

  • Generating health economics data to accelerate government health coverage of ctDNA testing
  • Enhancing Canexia Health’s ctDNA test to cover more solid tumor cancer types
  • Localizing testing access by training laboratory staff to conduct testing in-house

For thousands of cancer patients each year, this minimally-invasive blood draw can be performed instead of surgical tissue biopsy to enable oncologists to select treatment options.

Download Project ACTT Brochure

 

Testing Information

If you are a patient, you can learn more about how to access the test through your provider here.

If you are an oncologist/provider, you can learn more about test access for your patients here.

Tumour Types Tested

Breast, lung, and colorectal cancers

Eligibility

Patients with suspected or known relapsed disease where ctDNA testing can detect resistance mutations. Patients with metastatic disease where ctDNA testing can detect resistance mutations. Patients with tumor not easily amenable to biopsy. Very ill patients with metastatic disease.

Turnaround Time

10 working days

Specimen Type

Blood

Cost

Testing is available at no cost for 2,000 patients until March 31, 2021

One patient’s story

COVID-19 has created serious challenges for people living with advanced-stage cancer. In response, Canexia Health launched Project ACTT to provide liquid biopsy testing to 2,000 patients across Canada with advanced or metastatic breast, lung, and colorectal cancer.

More than 500 patients to date have participated in the program, which is mitigating the risk of COVID-19 exposure while ensuring access to targeted treatment selection despite tissue biopsy delays. Here is one patient’s story.

Read her story

A Global Blueprint

Using Project ACTT as a blueprint, Canexia Health is now building an ecosystem of partners to replicate the model globally and offset burdens on health systems by ensuring all eligible cancer patients have access to life-saving testing.

Canexia Health’s ctDNA test, Follow It®, offered through a growing network of global partners, is commercially available and detects close to 90% of clinically actionable mutations in all cancer types. Further, Canexia Health offers a unique partnership model for local laboratories to set up biomarker testing in-house quickly and effectively. Canexia Health provides its technology and methodology for labs to run testing in-house, while also providing a complete bioinformatics reporting pipeline.

Download Project ACTT Global Brochure

Partner with us

Partnering with Canexia Health is a cost-effective way to provide quality precision oncology testing and supports efforts to establish and secure reimbursement in localities. This will enable hospitals and laboratories to run ctDNA testing in-house, leading to a sustainable solution regardless of COVID-19 and other health system impacts.

We are seeking to further build our consortium of global pharmaceutical, laboratory, academic, and oncology partners for:

  • Sample collection
  • Bringing ctDNA testing in-house
  • Program funding support
  • Health economic studies
  • In-country health system expertise

Contact Us

Resources

In the News

February 4, 2021

Pilot of new cancer test in Canada shows promise as faster alternative to conventional biopsies

The COVID-19 pandemic has delayed thousands of surgical procedures across the country, including tissue biopsies needed for cancer diagnosis. But it’s also pushing demand for alternatives that allow patients to be tested for signs of tumours without even needing to enter a hospital. As part of a new pilot called Project ACTT, more than 800 Canadian cancer patients have been tested through liquid biopsies, which involve taking a blood sample and looking for signs of tumour DNA. That federally funded project, a partnership led by Vancouver-based Canexia Health, offers the potential for a more efficient alternative for cancer testing that can save hospital resources and lower the risk of infection.

Read More

Press

January 11, 2021

Canadian Program to Deploy Cancer Testing During COVID-19 Reaches Key Milestones, Adds New Partners

With a strategic investment from Canada’s Digital Technology Supercluster, Project ACTT is speeding up cancer testing for targeted treatment selection during the pandemic through a minimally invasive circulating tumor (ctDNA) DNA test, which is available as an alternative to some surgical tissue biopsies for patients with advanced lung, breast, or colorectal cancer.

Read More

Blog

Lab worker conducting tests at a lab

December 16, 2020

How to Ensure Equitable Access to Cancer Treatment Selection During and Beyond COVID-19

Earlier this year, Canexia Health launched Project ACTT, Access to Cancer Testing & Treatment in Response to COVID-19, with support from the Canadian federal government via the Digital Technology Supercluster. Through ACTT, we are leading a consortium of partners to speed up cancer testing in Canada for targeted treatment selection during the pandemic through minimally invasive circulating tumor (ctDNA) testing.

Read More